This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-Ley scFv to TNFα. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the Ley as well as the biological activity of TNFα. The rationale for fusing the scFv to the COOH terminus of TNF was to diminish the binding of the fusion protein to TNF receptors because the COOH terminus of TNF is involved in binding, and thus to partially inactivate (detoxify) the molecule. This molecule binds to LeY antigen on cancer cells with the same affinity as B1 (scFv) and B1 (scFv) immunotoxins but with significantly lower affinity to the TNF receptor compared to the TNF trimer. This immunocytokine was designed for treating Ley-expressing TNF-sensitive cancer.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-620 | Recombinant Anti-LeY Antibody | WB, IF, FuncS | IgG |
MHH-620 | Recombinant Human Anti-LeY Antibody | ELISA, IP, FuncS | IgG |
FAMAB-1325CQ | Human Anti-LeY Recombinant Antibody (clone H18A) | ELISA, IHC | Human IgG1 |
There are currently no Customer reviews or questions for ACFP-SH165. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.